How to optimize current treatment of genotype 2 hepatitis C virus infection

The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatmen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver international 2014-02, Vol.34 (s1), p.13-17
Hauptverfasser:	Marciano, Sebastián, Gadano, Adrián C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Algorithms Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use cirrhosis direct antiviral agents Drug Therapy, Combination - methods Drug Therapy, Combination - standards Genotype Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C - drug therapy Hepatitis C virus Humans Interferon-alpha - therapeutic use pegylated interferon Polyethylene Glycols - therapeutic use predictors of treatment response Recombinant Proteins - therapeutic use ribavirin Ribavirin - therapeutic use Standard of Care - trends Time Factors treatment duration Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!